Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2579406 | Thérapie | 2009 | 5 Pages |
Abstract
Treatment of patients with both atrial fibrillation and heart failure remains uneasy. In theory maintenance of sinus rhythm is desirable but the only pharmacological intervention able to do it safely is amiodarone. A trial of strategy randomisation, restoration of sinus rhythm or slowing of atrial fibrillation, has been done in patients with both atrial fibrillation and heart failure. This trial, named AF-CHF has shown neutral results, the 2 strategies, rhythm control or simple rate control were similar in terms of mortality. Dronedarone is an innovative drug bringing new possibilities in the treatment of atrial fibrillation but it is contra-indicated in case of severe heart failure. Another possible approach is that of non pharmacological techniques. Sinus rhythm maintenance may be obtained by pulmonary vein isolation. The other possibility is the ablation of atrio-ventricular node with implantation of a pacemaker, technique which is reserved to selected patients.
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
Jean-Yves Le Heuzey, Ãloi Marijon, Akli Otmani, Antoine Lepillier, Xavier Waintraub, Thomas Lavergne, Maurice Pornin,